RS50849B - Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method - Google Patents
Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive methodInfo
- Publication number
- RS50849B RS50849B RSP-2009/0247A RSP20090247A RS50849B RS 50849 B RS50849 B RS 50849B RS P20090247 A RSP20090247 A RS P20090247A RS 50849 B RS50849 B RS 50849B
- Authority
- RS
- Serbia
- Prior art keywords
- estradiolvalerate
- units
- daily dose
- dienogest
- phase
- Prior art date
Links
Abstract
Primena estradiolvalerata u kombinaciji sa 17a-cijanometil-17-hidroksiestra-4,9-dien-3-on (dienogest), naznačena time da sadržavaprvu fazu sa 2 jedinice dnevne doze estradiolvalerata do 3 mg,drugu fazu sa 2 grupe jedinice dnevne doze, pri čemu prva grupa sadržava 5 jedinica dnevne doze kombinacije 2 mg estradiolvalerata i 2 mg dienogesta,i druga grupa sadržava 17 jedinica dnevne doze kombinacije 2 mg estradiolvalerata i 3 mg dienogesta,treću fazu sa 2 jedinice dnevne doze sa 1 mg estradiolvalerata i jednu dodatnu fazu sa 2 jedinice dnevne doze farmaceutski neškodljivog placebaza izradu višefaznog kombinovanog preparata sa ukupnim brojem od 28 jedinica dnevne doze za oralnu terapiju disfunkcionalnog uterinog krvarenja, gde se podrazumeva menstrualno krvarenje duže od 7 dana, zajedno sa oralnom kontracepcijom.Administration of estradiolvalerate in combination with 17a-cyanomethyl-17-hydroxyester-4,9-dien-3-one (dienogest), comprising the first phase of 2 units of daily dose of estradiolvalerate to 3 mg, the second phase of 2 groups of units of daily dose. wherein the first group contains 5 units of daily dose of a combination of 2 mg estradiolvalerate and 2 mg dienogest, and the second group contains 17 units of a daily dose of a combination of 2 mg estradiolvalerate and 3 mg phase, the third phase with 2 units of a daily dose of 1 mg estradiolvalerate and one additional phase with 2 units of daily dose of pharmaceutically harmless placebase production of a multiphase combination preparation with a total of 28 units of daily dose for oral therapy of dysfunctional uterine bleeding, which involves menstrual bleeding for more than 7 days, together with oral contraception.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RSP-2009/0247A RS50849B (en) | 2005-10-13 | 2005-10-13 | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RSP-2009/0247A RS50849B (en) | 2005-10-13 | 2005-10-13 | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS50849B true RS50849B (en) | 2010-08-31 |
Family
ID=43807097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RSP-2009/0247A RS50849B (en) | 2005-10-13 | 2005-10-13 | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method |
Country Status (1)
| Country | Link |
|---|---|
| RS (1) | RS50849B (en) |
-
2005
- 2005-10-13 RS RSP-2009/0247A patent/RS50849B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20070188B1 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| EA200900491A1 (en) | USE OF ESTRADIOL VALERAT OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST FOR ORAL TREATMENT TO MAINTAIN AND / OR INCREASE SEXUAL TREATMENT IN THE SPECIAL WOMAN | |
| RU2009148278A (en) | The use of estriol in a low dose | |
| RS50972B (en) | Pharmaceutical composition containing gestagens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate | |
| HRP20121072T1 (en) | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring | |
| NZ591627A (en) | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology | |
| HRP20100513T1 (en) | Multi-phase contraceptive preparation based on a natural estrogen | |
| JP2005516913A5 (en) | ||
| AR065816A1 (en) | ORAL CONTRACEPTIVE REGIME | |
| HRP20090256T1 (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| NO20072687L (en) | Pharmaceutical contraceptive preparation | |
| RS50849B (en) | Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method | |
| EA200701389A1 (en) | SOLID ORAL MEDICAL FORM FOR CONTRACEPTION | |
| AR065971A1 (en) | NEW DROSPERINONA / 17BETA-ESTRADIOL REGIME, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION | |
| AR049195A1 (en) | USE OF A COMBINATION OF ETHINYLESTRADIOL AND ACETATE OF CLORMADINONE FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
| CY1112775T1 (en) | USE OF VALERIAN OSTRADIOLIS IN CONNECTION WITH DIENOGEST FOR ORAL TREATMENT OF MUTRAL DISORDER BLOOD TREATMENT IN AITITA | |
| PE20070769A1 (en) | PROCEDURE FOR THE PRODUCTION OF A MONOPHASIC PHARMACEUTICAL PREPARATION FOR ORAL THERAPY OF DYSFUNCTIONAL UTERINE HEMORRHAGE | |
| BR0311209A (en) | Method of producing pharmaceutical dosage units for oral administration, use of etonogestrel, and tablet | |
| UY29378A1 (en) | PHARMACEUTICAL PREPARATION FOR ORAL ANTI-CONCEPTION | |
| HRP20020666B1 (en) | Drospirenone for hormone replacement therapy | |
| RU2009140372A (en) | NEW MODE WITH DROSPIRENONE / 17B-ESTRADIOL, PHARMACEUTICAL COMBINED PRODUCT AND KIT FOR THE PERFORMANCE OF THIS MODE | |
| RU2008149412A (en) | USE OF DROSPIRENONE TO PREVENT HIGH BLOOD PRESSURE IN PATIENTS WITH PREHYPERTENSION |